Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
7Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
SAB Biotherapeutics, Inc. (SABS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
3Distinct source URLs
6High confidence
0.777Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
SAB Biotherapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
DAKOTA-AG-PROPERTIES
DAKOTA-AG-PROPERTIES
92%
In December 2018, the Company entered into a finance lease with Dakota Ag Properties for a new animal facility which includes the surrounding land.
EMERGENT
EMERGENT
90%
Emergent has the sole and exclusive right to manufacture the Product during the term of the MSA
FORTREA
FORTREA
90%
The Company expects to make ongoing payments to Fortrea over the next 12 to 18 months in connection with services provided by Fortrea, as well as clinical trial site and other pass-through costs rela…
Reciprocal relationship from BDRX graph: Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from SABS graph: Reciprocal relationship from BDRX g…
Reciprocal relationship from EBS graph: Reciprocal relationship from SABS graph: gal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of un…
gal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates: (i) the rules and regulations of the F…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SABS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SABS graph: Reciprocal relationship from SNYN…
SNYNF
Sanofi
72%
ct pipeline and that may outperform or be more competitive than our products. For example, there are multiple products that may be competitive with SAB-142 for T1D such as animal-derived polyclonal b…
BIG-CYPRESS-HOLDINGS-LLC
BIG-CYPRESS-HOLDINGS-LLC
62%
reference to the quoted market price. The Public Warrants were classified as a Level 1 fair value measurement, due to the use of the quoted market price, and the Private Placement Warrants held priva…
EMERGENT-BIOSOLUTIONS-CANADA-INC
EMERGENT-BIOSOLUTIONS-CANADA-INC
62%
gal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violates: (i) the rules and regulations of the F…
UBS-SECURITIES-LLC
UBS-SECURITIES-LLC
62%
ctuate on a quarterly and annual basis, which may result in a decline in our stock price if such fluctuations result in a failure to meet the expectations of securities analysts or investors. Our ope…
SAB Biotherapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SABS-DEBT-12349
Warrants outstanding: 2753246
90%
xbrl warrant detail from xbrl 2026-03-31.
SABS-DEBT
Debt stack $6.2M
90%
Market cache reports total debt of $6.2M.
SAB Biotherapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for SAB Biotherapeutics, Inc..
SAB Biotherapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
SABS-OWNER-VIVO-CAPITAL-LLC
Vivo Capital, LLC
90%
13F overlay lists Vivo Capital, LLC as top holder; 79 tracked holders.
SAB Biotherapeutics, Inc. Extended Supply Chain Network
